دورية أكاديمية
أعرض في EDS

Chemotherapy-induced intestinal epithelial damage directly promotes galectin-9-driven modulation of T cell behavior.

التفاصيل البيبلوغرافية
العنوان: Chemotherapy-induced intestinal epithelial damage directly promotes galectin-9-driven modulation of T cell behavior.
المؤلفون: Jansen SA; Division of Pediatrics, University Medical Center Utrecht, Utrecht 3584GX, the Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht 3584CS, the Netherlands.; Regenerative Medicine Center, University Medical Center Utrecht, Utrecht 3584CT, the Netherlands., Cutilli A; Regenerative Medicine Center, University Medical Center Utrecht, Utrecht 3584CT, the Netherlands.; Center of Molecular Medicine, University Medical Center Utrecht, Utrecht 3584CG, the Netherlands., de Koning C; Princess Máxima Center for Pediatric Oncology, Utrecht 3584CS, the Netherlands.; Center for Translational Immunology, University Medical Center Utrecht, 3584GX Utrecht, the Netherlands., van Hoesel M; Division of Pediatrics, University Medical Center Utrecht, Utrecht 3584GX, the Netherlands.; Regenerative Medicine Center, University Medical Center Utrecht, Utrecht 3584CT, the Netherlands., Frederiks CL; Regenerative Medicine Center, University Medical Center Utrecht, Utrecht 3584CT, the Netherlands.; Center of Molecular Medicine, University Medical Center Utrecht, Utrecht 3584CG, the Netherlands., Saiz Sierra L; Division of Pediatrics, University Medical Center Utrecht, Utrecht 3584GX, the Netherlands.; Regenerative Medicine Center, University Medical Center Utrecht, Utrecht 3584CT, the Netherlands., Nierkens S; Princess Máxima Center for Pediatric Oncology, Utrecht 3584CS, the Netherlands.; Center for Translational Immunology, University Medical Center Utrecht, 3584GX Utrecht, the Netherlands., Mokry M; Division of Pediatrics, University Medical Center Utrecht, Utrecht 3584GX, the Netherlands.; Department of Cardiology, University Medical Center Utrecht, Utrecht 3584GX, the Netherlands., Nieuwenhuis EES; Division of Pediatrics, University Medical Center Utrecht, Utrecht 3584GX, the Netherlands.; Regenerative Medicine Center, University Medical Center Utrecht, Utrecht 3584CT, the Netherlands.; University College Roosevelt, Utrecht University, Middelburg 4331CB, the Netherlands., Hanash AM; Departments of Medicine and Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY 10065, USA., Mocholi E; Regenerative Medicine Center, University Medical Center Utrecht, Utrecht 3584CT, the Netherlands.; Center of Molecular Medicine, University Medical Center Utrecht, Utrecht 3584CG, the Netherlands., Coffer PJ; Division of Pediatrics, University Medical Center Utrecht, Utrecht 3584GX, the Netherlands.; Regenerative Medicine Center, University Medical Center Utrecht, Utrecht 3584CT, the Netherlands.; Center of Molecular Medicine, University Medical Center Utrecht, Utrecht 3584CG, the Netherlands., Lindemans CA; Division of Pediatrics, University Medical Center Utrecht, Utrecht 3584GX, the Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht 3584CS, the Netherlands.; Regenerative Medicine Center, University Medical Center Utrecht, Utrecht 3584CT, the Netherlands.
المصدر: IScience [iScience] 2024 May 22; Vol. 27 (6), pp. 110072. Date of Electronic Publication: 2024 May 22 (Print Publication: 2024).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Cell Press Country of Publication: United States NLM ID: 101724038 Publication Model: eCollection Cited Medium: Internet ISSN: 2589-0042 (Electronic) Linking ISSN: 25890042 NLM ISO Abbreviation: iScience Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [Cambridge, MA] : Cell Press, [2018]-
مستخلص: The intestine is vulnerable to chemotherapy-induced damage due to the high rate of intestinal epithelial cell (IEC) proliferation. We have developed a human intestinal organoid-based 3D model system to study the direct effect of chemotherapy-induced IEC damage on T cell behavior. Exposure of intestinal organoids to busulfan, fludarabine, and clofarabine induced damage-related responses affecting both the capacity to regenerate and transcriptional reprogramming. In ex vivo co-culture assays, prior intestinal organoid damage resulted in increased T cell activation, proliferation, and migration. We identified galectin-9 (Gal-9) as a key molecule released by damaged organoids. The use of anti-Gal-9 blocking antibodies or CRISPR/Cas9-mediated Gal-9 knock-out prevented intestinal organoid damage-induced T cell proliferation, interferon-gamma release, and migration. Increased levels of Gal-9 were found early after HSCT chemotherapeutic conditioning in the plasma of patients who later developed acute GVHD. Taken together, chemotherapy-induced intestinal damage can influence T cell behavior in a Gal-9-dependent manner which may provide novel strategies for therapeutic intervention.
Competing Interests: The authors declare no conflicts of interest.
(© 2024 The Author(s).)
التعليقات: Update of: bioRxiv. 2023 Apr 30:2023.04.30.538862. doi: 10.1101/2023.04.30.538862. (PMID: 37163028)
References: Expert Rev Clin Immunol. 2010 Jul;6(4):559-66. (PMID: 20594129)
J Immunol Methods. 2005 May;300(1-2):124-35. (PMID: 15896801)
Genome Biol. 2014;15(12):550. (PMID: 25516281)
Cancer Lett. 2021 Jul 10;510:67-78. (PMID: 33895262)
Curr Opin Struct Biol. 2002 Oct;12(5):616-23. (PMID: 12464313)
Nat Med. 2002 Jun;8(6):575-81. (PMID: 12042807)
Leukemia. 2010 Apr;24(4):679-86. (PMID: 20130602)
Nat Rev Immunol. 2020 May;20(5):279-293. (PMID: 31853049)
Cell Mol Gastroenterol Hepatol. 2021;11(1):13-32. (PMID: 32745639)
Bioinformatics. 2009 Jul 15;25(14):1754-60. (PMID: 19451168)
Blood. 2012 Jan 5;119(1):296-307. (PMID: 22010102)
Inflammation. 2012 Apr;35(2):633-7. (PMID: 21717191)
Bone Marrow Transplant. 2001 Oct;28(8):737-42. (PMID: 11781624)
PLoS One. 2014 Apr 22;9(4):e95192. (PMID: 24755770)
Sci Immunol. 2019 Dec 6;4(42):. (PMID: 31811055)
J Immunol. 2020 Mar 1;204(5):1158-1172. (PMID: 31969388)
J Innate Immun. 2021;13(5):295-305. (PMID: 34182560)
Lancet. 2009 May 2;373(9674):1550-61. (PMID: 19282026)
Biol Blood Marrow Transplant. 2011 Jun;17(6):893-900. (PMID: 20946966)
Nat Med. 2011 Nov 29;18(1):135-42. (PMID: 22127134)
Biochem Pharmacol. 2011 Jan 15;81(2):222-32. (PMID: 20933509)
Nature. 2020 Feb;578(7796):600-604. (PMID: 32051586)
Biol Blood Marrow Transplant. 2014 Mar;20(3):345-53. (PMID: 24315842)
Nature. 2015 Dec 24;528(7583):560-564. (PMID: 26649819)
Mucosal Immunol. 2015 Nov;8(6):1226-36. (PMID: 25736457)
J Immunol. 2017 Oct 15;199(8):2721-2728. (PMID: 28877989)
Nature. 2009 May 14;459(7244):262-5. (PMID: 19329995)
Eur J Immunol. 2011 Jan;41(1):67-75. (PMID: 21182078)
Cell. 2022 Jan 20;185(2):283-298.e17. (PMID: 35021065)
Nat Commun. 2021 Feb 5;12(1):832. (PMID: 33547304)
Nat Protoc. 2020 Dec;15(12):4000-4033. (PMID: 33169003)
Biol Blood Marrow Transplant. 2016 Oct;22(10):1792-1800. (PMID: 27377901)
Int Immunopharmacol. 2020 Nov;88:106929. (PMID: 32889240)
Cell. 2018 Nov 15;175(5):1307-1320.e22. (PMID: 30392957)
Mucosal Immunol. 2022 Apr;15(4):605-619. (PMID: 35654837)
Clin Gastroenterol Hepatol. 2013 Sep;11(9):1075-83. (PMID: 23851019)
Immunity. 2014 Aug 21;41(2):270-82. (PMID: 25065622)
Gastroenterology. 2011 Nov;141(5):1762-72. (PMID: 21889923)
Inflamm Bowel Dis. 2021 Jan 19;27(2):256-267. (PMID: 32556182)
J Biochem. 2007 Feb;141(2):157-72. (PMID: 17167046)
Science. 2016 Jun 24;352(6293):1581-6. (PMID: 27256884)
Gastroenterology. 2020 Dec;159(6):2092-2100.e5. (PMID: 32791132)
Biol Blood Marrow Transplant. 2017 Feb;23(2):285-292. (PMID: 27816651)
Bone Marrow Transplant. 2021 Jun;56(6):1426-1432. (PMID: 33469191)
EMBO J. 2019 Jun 17;38(12):. (PMID: 31036555)
Dig Dis Sci. 2007 Sep;52(9):2340-5. (PMID: 17415646)
J Biol Chem. 1997 Mar 7;272(10):6416-22. (PMID: 9045665)
J Clin Invest. 1995 Jun;95(6):2945-53. (PMID: 7769137)
J Biol Chem. 2022 Apr;298(4):101821. (PMID: 35283189)
Cancer. 2003 Oct 1;98(7):1531-9. (PMID: 14508842)
Nat Methods. 2012 Jun 28;9(7):676-82. (PMID: 22743772)
Nature. 2022 Apr;604(7906):563-570. (PMID: 35418687)
Proc Natl Acad Sci U S A. 2011 Jun 28;108(26):10650-5. (PMID: 21670307)
Biochimie. 2001 Sep;83(9):851-62. (PMID: 11698107)
Nat Immunol. 2005 Dec;6(12):1245-52. (PMID: 16286920)
Gastroenterology. 2020 Jul;159(1):96-104. (PMID: 32165208)
J Clin Invest. 2019 Feb 1;129(2):902-914. (PMID: 30667372)
Blood. 2011 Mar 17;117(11):3214-9. (PMID: 21263156)
J Biol Chem. 2015 Jul 3;290(27):16797-811. (PMID: 25947381)
Biol Blood Marrow Transplant. 2012 Dec;18(12):1819-26. (PMID: 22750645)
J Exp Med. 2014 Jun 30;211(7):1433-48. (PMID: 24958847)
Cell. 2018 Sep 6;174(6):1586-1598.e12. (PMID: 30100188)
Immunity. 2019 Jul 16;51(1):90-103.e3. (PMID: 31278057)
Curr Opin Struct Biol. 2007 Oct;17(5):513-20. (PMID: 17950594)
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50. (PMID: 16199517)
J Hematol Oncol. 2022 May 19;15(1):65. (PMID: 35590415)
Oncogene. 2022 May;41(19):2719-2733. (PMID: 35393546)
Blood. 2012 Jul 19;120(3):682-90. (PMID: 22677125)
Biol Blood Marrow Transplant. 2010 Nov;16(11):1567-75. (PMID: 20546909)
Nat Rev Gastroenterol Hepatol. 2017 Jan;14(1):9-21. (PMID: 27848962)
Ann Gastroenterol. 2012;25(2):106-118. (PMID: 24713845)
Cancer Res. 2020 Mar 1;80(5):1219-1227. (PMID: 31690670)
Blood. 2019 Dec 12;134(24):2139-2148. (PMID: 31697827)
J Biol Chem. 1997 Feb 28;272(9):6078-86. (PMID: 9038233)
Cancer Sci. 2004 May;95(5):454-8. (PMID: 15132775)
Front Pediatr. 2021 Dec 10;9:775485. (PMID: 34956984)
PLoS One. 2013 May 31;8(5):e65616. (PMID: 23741502)
Blood Adv. 2022 Mar 22;6(6):1719-1730. (PMID: 34781362)
Cell. 2017 Nov 2;171(4):783-794.e13. (PMID: 28942917)
J Immunol. 2003 Apr 1;170(7):3631-6. (PMID: 12646627)
Immunity. 2019 Nov 19;51(5):885-898.e7. (PMID: 31542340)
Cell Immunol. 2017 Jun;316:70-76. (PMID: 28413062)
Bone Marrow Transplant. 2015 Apr;50(4):559-65. (PMID: 25531281)
N Engl J Med. 2018 Feb 8;378(6):586. (PMID: 29414273)
Nature. 2014 Sep 25;513(7519):564-568. (PMID: 25043027)
Oncogene. 2008 Oct 27;27(50):6522-37. (PMID: 18955977)
معلومات مُعتمدة: P30 CA008748 United States CA NCI NIH HHS; R01 HL145631 United States HL NHLBI NIH HHS; R01 HL146338 United States HL NHLBI NIH HHS
فهرسة مساهمة: Keywords: Cancer; Immunology; Molecular biology; Stem cells research
تواريخ الأحداث: Date Created: 20240617 Latest Revision: 20240806
رمز التحديث: 20240806
مُعرف محوري في PubMed: PMC11176658
DOI: 10.1016/j.isci.2024.110072
PMID: 38883813
قاعدة البيانات: MEDLINE
الوصف
تدمد:2589-0042
DOI:10.1016/j.isci.2024.110072